Prostate Cancer News and Research RSS Feed - Prostate Cancer News and Research Twitter

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Further Reading
Loyola offers holistic approach to help couples manage their sexual health

Loyola offers holistic approach to help couples manage their sexual health

Cancer and cancer therapies are frequently associated with sexual dysfunction, yet this condition often goes untreated, according to specialists at Loyola Medicine's Sexual Wellness Clinic. [More]
Roswell Park, Lakeshore Cancer Center partner to improve access to cancer care for Nigerians

Roswell Park, Lakeshore Cancer Center partner to improve access to cancer care for Nigerians

America's oldest cancer center and one of the world's newest oncology centers are partnering to improve access to cancer prevention, screening and care for the people of Nigeria. Roswell Park Cancer Institute and Lakeshore Cancer Center have announced an affiliation that will see Roswell Park faculty providing clinical consultations to assist LCC oncologists, who will also have access to both training at RPCI and continuing professional education seminars they can participate in remotely. [More]
Aeterna Zentaris recruits patients for ZoptEC Phase 3 study in women with advanced endometrial cancer

Aeterna Zentaris recruits patients for ZoptEC Phase 3 study in women with advanced endometrial cancer

Aeterna Zentaris Inc. today announced it has reached its goal of recruiting 500 patients for its pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) clinical study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer. [More]
New species of tRNA-derived small RNAs contribute to cell proliferation in cancer

New species of tRNA-derived small RNAs contribute to cell proliferation in cancer

Since their discovery in the 1950s, transfer RNAs (tRNAs) have been best known for their role in helping the cell make proteins from messenger RNA templates. However, recent studies have led to a previously-unsuspected concept that tRNAs are not always the end product; namely, they further serve as a source of small RNAs. [More]
Wistar Institute study shows that PI3K inhibitors may make a patient's cancer even worse

Wistar Institute study shows that PI3K inhibitors may make a patient's cancer even worse

The enzyme phosphatidylinositol-3 kinase (PI3K) appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target, with many PI3K-inhibiting drugs currently in various stages of clinical development. However, PI3K inhibitors have only shown modest clinical activity with patients who receive these drugs experiencing very little improvement in survival. [More]
Concordia Healthcare's common shares to begin trading on NASDAQ under symbol CXRX

Concordia Healthcare's common shares to begin trading on NASDAQ under symbol CXRX

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, today announced that its common shares will begin trading on the NASDAQ Global Select Market on June 29, 2015 under the symbol CXRX. [More]
VolitionRx teams up with market access consulting agencies to support access of NuQ cancer tests across Europe

VolitionRx teams up with market access consulting agencies to support access of NuQ cancer tests across Europe

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has established partnerships with two prominent market access consulting agencies, DecideumCogentia and MedPass International, to support market access of its NuQ® cancer tests across Europe. [More]
Novogen’s chemotherapy drug Anisina proves as effective anti-cancer agent in animals

Novogen’s chemotherapy drug Anisina proves as effective anti-cancer agent in animals

US-Australian drug discovery company, Novogen Limited announced today that its candidate cytotoxic chemotherapy drug, Anisina, has proved an effective anti-cancer agent in animals, the result of which it now has been fast-tracked by the Company to come into the clinic. [More]
Targeted molecular-imaging method could help identify early stages of prostate cancer

Targeted molecular-imaging method could help identify early stages of prostate cancer

A targeted molecular-imaging method under development at Rochester Institute of Technology could help detect early stages of prostate cancer and improve image-directed biopsies. [More]
PSMA can be an ideal target for diagnosis and treatment of prostate cancer

PSMA can be an ideal target for diagnosis and treatment of prostate cancer

Prostate-specific membrane antigen (PSMA) is a surface protein that is normally present on healthy prostate cells, but is found at much higher levels on prostate cancer cells. It is barely found in the rest of the body. "Therefore, PSMA is an ideal target for diagnostic purposes as well as targeted therapies against prostate cancer," says biotechnologist Dr. Matthias Eder of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ). [More]
International study provides evidence of clear link between smoking and risk of prostate cancer

International study provides evidence of clear link between smoking and risk of prostate cancer

Smoking is a known risk factor for the development of various forms of cancer. However, when it comes to the link between smoking and prostate cancer, the findings of previous studies have been contradictory. Now, for the first time, an international study led by MedUni Vienna and Basle University Hospital, has provided evidence of a clear link. [More]
Study shows 28% decline in prostate cancer diagnoses following USPSTF recommendation against PSA testing

Study shows 28% decline in prostate cancer diagnoses following USPSTF recommendation against PSA testing

A new study led by Vanderbilt University Medical Center investigators found new diagnoses of prostate cancer in the U.S. declined 28 percent in the year following the draft recommendation from the United States Preventive Services Task Force against routine PSA screening for men. [More]
PCF, MLB partner to raise awareness and research funding for prostate cancer

PCF, MLB partner to raise awareness and research funding for prostate cancer

The Prostate Cancer Foundation and Major League Baseball are once again stepping up to the plate to hit home runs for prostate cancer research and encourage fans to "Keep Dad in the Game" as part of the 20th Annual Home Run Challenge. This hallmark event will take place during the six days leading up to Fathers' Day and will help raise crucial awareness and much needed research funding for prostate cancer. [More]
Simple test could help identify genetically inherited risk for prostate cancer

Simple test could help identify genetically inherited risk for prostate cancer

Men with an elevated, genetically inherited risk for prostate cancer could be routinely identified with a simple blood or urine test, scientists at UC San Francisco and Kaiser Permanente Northern California have concluded, potentially paving the way to better or earlier diagnosis. [More]
Heparin market in Europe estimated to reach USD 3,148.0 million by 2022

Heparin market in Europe estimated to reach USD 3,148.0 million by 2022

According to a new market report published by Transparency Market Research Heparin Market - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022" the Heparin Market Europe was valued at USD 2,004.5 million in 2013 and is estimated to reach USD 3,148.0 million by 2022 growing with a CAGR of 5.2% from 2014 to 2022. [More]
Researchers reveal that Helicobacter pylori infection can lead to gastric cancer

Researchers reveal that Helicobacter pylori infection can lead to gastric cancer

Around half of the global population is chronically infected with the stomach bacterium Helicobacter pylori, almost 1 percent of whom go on to develop gastric adenocarcinoma, one of the deadliest forms of cancer. Usually it takes many decades for the cancer to develop, making it difficult to pinpoint exactly how it is linked to an infection. [More]
Nanoplatform technology that detects early stages of cancer receives U.S. patent

Nanoplatform technology that detects early stages of cancer receives U.S. patent

A U.S. patent has been awarded to a Kansas State University technology that quickly detects the early stages of cancer before physical symptoms ever appear. [More]
Scientists identify two new key players involved in development of prostate cancer

Scientists identify two new key players involved in development of prostate cancer

Understanding how a normal healthy cell turns into a cancerous one is our best bet yet for beating the disease. It will help better diagnose the cancer type, and enable the development of more effective, and less toxic therapies. But cells have evolved all sorts of sophisticated ways to become cancerous, and identifying the molecules involved and how they function in each type of cancer is a major undertaking. [More]
Samadi Robotics Foundation gets donation to find cure for prostate cancer

Samadi Robotics Foundation gets donation to find cure for prostate cancer

World renowned robotic prostate cancer surgeon, Dr. David B. Samadi, was awarded the Peter Latos Prostate Cancer Foundation Award last Thursday at the Foundation's 2nd Annual Gala where he was honored in recognition of his faithful service for the treatment, prevention and innovation in the fight against prostate cancer. [More]
Study highlights discovery of genetic variants linked to mucinous ovarian carcinomas

Study highlights discovery of genetic variants linked to mucinous ovarian carcinomas

New research by an international team including Keck Medicine of USC scientists is bringing the origins of ovarian cancer into sharper focus. [More]
Advertisement
Advertisement